TELA Bio (TELA) Short term Debt (2025)
TELA Bio's (TELA) quarterly Short term Debt came in at $3.3 million in Q2 2025.
TELA Bio (TELA) Short term Debt (2025) Analysis & Trends
TELA Bio's Short term Debt history runs 1 years deep, the most recent figure standing at $3.3 million for Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 180.89 Bn | 173.59 Bn | 6.27 Bn |
| 2 | Stryker | 127.82 Bn | 124.94 Bn | 3.81 Bn |
| 3 | Medtronic | 107.49 Bn | 98.27 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.24 Bn | 65.78 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.02 Bn | 44.34 Bn | 1.29 Bn |
| 6 | Dexcom | 28.25 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 28.17 Bn | 25.89 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.72 Bn | 26.14 Bn | - |
| 9 | Koninklijke Philips | 25.31 Bn | 22.19 Bn | 2.07 Bn |
| 10 | TELA Bio | 38.93 Mn | -606,567.35 | 12.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 3.33 Mn |